Immune system reset: CAR T-Cells take on autoimmune diseases

NCT ID NCT07161193

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe and can control the disease by targeting and destroying faulty immune cells.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
CD19 CAR T-cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new way to control severe autoimmune diseases that haven't responded to other treatments, potentially reducing symptoms and need for ongoing medications.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. There are serious risks like cytokine release syndrome and nerve toxicity, and it's unclear if the effects will last without continued treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China

    Luoyang, Henan, 471003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.